---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113210"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:15:48.209124+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma terminates CFO/CBO and COO/CDO; grants retention equity to CEO and VP Finance

## Summary
- Andrew Gengos (CFO/CBO) and Rachel Lenington (COO/CDO) terminated Oct 1, 2024; severance payments of $363,750 and $375,000 respectively.
- Lenington to provide consulting through Dec 31, 2024 at $41,666.67/month; equity vests during term.
- CEO Mark Litton receives 325k RSUs + 325k options (strike $0.4257); VP Finance Renninger gets 37,077 RSUs + 37,077 options (strike $0.4499).
- Retention awards vest 1/3 each on Dec 31, 2024, Jun 30, 2025, and Dec 31, 2025, subject to continued service.
- 2024 corporate goal achievement percentage automatically increased by 25 percentage points for certain executives.

## SEC filing metadata
- accession: 0000950170-24-113210
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017024113210/0000950170-24-113210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017024113210/atha-20241001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113210
- JSON: https://secwatch.observer/filing/0000950170-24-113210.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.